Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus chemotherapy as neoadjuvant therapy for limited-stage small cell lung cancer
ChiCTR2100042367Phase 4Recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atezolizumab in small cell lung cancer (SCLC), sponsored by Beijing Chest Hospital. Primary endpoint: major pathologic response. Started Feb 2021; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100042367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042367.